HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

NBI-5788 Neurocrine.

Abstract
Neurocrine Biosciences is developing NBI-5788, an analog of an immunodominant epitope of myelin basic protein for the potential intravenous treatment of multiple sclerosis. By April 2005, enrollment for phase II trials was complete, with results expected early in 2006.
AuthorsCynthia L Darlington
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 6 Issue 7 Pg. 747-51 (Jul 2005) ISSN: 1472-4472 [Print] England
PMID16044672 (Publication Type: Journal Article, Review)
Chemical References
  • Myelin Basic Protein
  • Neurotransmitter Agents
  • Peptide Fragments
  • NBI 5788
Topics
  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Multiple Sclerosis (drug therapy)
  • Myelin Basic Protein (immunology, therapeutic use)
  • Neurotransmitter Agents (immunology, therapeutic use)
  • Peptide Fragments (immunology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: